GlassScriptPhysician profile
Greg Richard Angstreich
NPI 1659303873
$5,478.10
in general payments reported to CMS, 2019-2025
12 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,881 · 2020: $18.44 · 2021: $28.45 · 2022: $169 · 2023: $152 · 2024: $101 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $271 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $270.81 |
| Education | $110.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $4,799.85 | 2019 | |
| Janssen Biotech, INC. | $150.51 | 2024-2025 | Erleada, Balversa, Akeega |
| E.R. Squibb & Sons, L.L.C. | $121.63 | 2022 | |
| Steris Corporation | $113.82 | 2023 | |
| Genentech USA, INC. | $65.00 | 2019 | |
| Amgen INC. | $50.66 | 2019-2021 | |
| Pfizer INC. | $47.54 | 2022 | |
| Glaxosmithkline, LLC. | $36.33 | 2024-2025 | Jemperli, Zejula |
| Aveo Pharmaceuticals, INC. | $29.96 | 2023-2024 | Fotivda |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $25.18 | 2023 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Angstreich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.